Skip to content

Propofol-Dexmedetomine Adjunction in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery :Effect on Anesthetic Consumption ,Perioperative Outcomes,and Early Recovery

Propofol-Dexmedetomine Adjunction in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery :Effect on Anesthetic Consumption ,Perioperative Outcomes,and Early Recovery : Randomized Controlled Trial

Status
Not yet recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07798089
Enrollment
60
Registered
2026-09-01
Start date
2026-09-01
Completion date
2027-01-15
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery

Keywords

propofol , Dexmedetomidine ,Minimally Invasive Cardiac Valve Surgery

Brief summary

Propofol-Dexmedetomidine Adjunction in Balanced Anesthesia for Minimally Invasive Cardiac Valve Surgery: Effects on Anesthetic Consumption, perioperative outcomes, and Early Recovery

Detailed description

This prospective, randomized, double-blind study was conducted to evaluate the effect of dexmedetomidine as an adjunct to propofol-based anesthesia in patients undergoing minimally invasive cardiac valve surgery. Patients were randomly allocated to receive either dexmedetomidine or placebo in addition to standard propofol-based anesthesia. The primary outcome was total propofol consumption during surgery. Secondary outcomes included intraoperative hemodynamic parameters, anesthetic and recovery characteristics, and postoperative outcomes.

Interventions

Thirty patients will receive a continuous infusion of propofol at a rate of 2 mg/kg/h and 50 cc 0.9% sodium chloride solution infused at a rate of 0.4 µg/kg/h (used as a placebo).

DRUGpropofol and dexmetomidine

patients will receive a continuous infusion of propofol at a rate of 2 mg/kg/h in addition to dexmedetomidine at a rate of 0.4 µg/kg/h.

Sponsors

Kafrelsheikh University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. patients belonging to American Society of Anesthesiologists (ASA) class I or II 2. patients scheduled for minimally invasive cardiac valve surgery.

Exclusion criteria

1. patient more than 60 years 2. patients having neurological/psychological disorders, 3. patient having severe systemic disorders (renal/hepatic dysfunction and severe respiratory disorder), 4. patient with history of allergy to the study drugs, 5. patient with left ventricular ejection fraction \< 40%,

Design outcomes

Primary

MeasureTime frameDescription
total intraoperative isoflurane consumption between propofol dexmedetomidine anesthesia and propofol anesthesia alone under entropy-guided anesthesiaTime Frame: From induction of anesthesia until discontinuation of anesthesia; total isoflurane consumption will be recorded at the end of surgery.Total intraoperative isoflurane consumption Description: The total amount of isoflurane consumed during anesthesia will be compared between patients receiving propofol-dexmedetomidine anesthesia and those receiving propofol anesthesia alone under entropy-guided anesthesia. Isoflurane consumption will be assessed from induction of anesthesia until discontinuation of anesthesia and measured as the total volume consumed. (ML\\MIN)

Contacts

CONTACTDonia Hany Hany, MD
doniahany1788@gmail.com01014498540

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026